SAE1 (SUMO1 Activating Enzyme Subunit 1)

Targeting these pathways with inhibitors, such as topotecan and chlorogenic acid, may provide novel treatment strategies. Furthermore, SUMOylation-driven alterations in transcription factors and DNA repair mechanisms contribute to therapy resistance. Understanding these mechanisms could pave the way for innovative interventions in glioblastoma management.

In contrast, other antibody positive patients had a 100% survival rate. This comprehensive analysis of a southern Chinese IIM cohort underscores that MSA profiles can effectively stratify patients into clinically distinct subgroups, which is crucial for predicting specific organ involvement, prognosis, and developing tailored treatment strategies.

Notably, the silencing of p53 rescued the immune evasion impeded by SAE1 knockdown, and SAE1 overexpression also rescued the antitumor benefits of sh-ZNF184. Overall, this study elucidates that abnormally reduced methylation of ZNF184 mediates transcriptional activation of SAE1 and impedes p53 expression through SUMOylation, thereby governing cell cycle arrest and promoting immune evasion in the NSCLC progression.

This highlights the importance of comprehensive cancer screening in patients with unusual dermatomyositis presentations. https://www.europeanreview.org/wp/wp-content/uploads/Graphical-Abstract-rev.jpg.

In clinical application, we used sputum samples from patients with lung cancer or chronic pulmonary obstructive pulmonary disease for protein profiling and further used sputum-based thin-slice technology for experimental verification, which confirmed the application potential of SAE1 in the diagnosis of lung cancer patients. In summary, our findings reveal a critical role for SAE1 as an oncogene in lung cancer cells and suggest that SAE1 may be used for the diagnosis of lung cancer patients.

Its activity was effectively counteracted by TAK-981, a SUMO inhibitor that demonstrated significant therapeutic potential by suppressing RMS cell proliferation and migration, and enhancing the cytotoxic effects of chemotherapeutic agents actinomycin D and doxorubicin. The findings of this study establish TAK-981 as a promising therapeutic agent for RMS. The results also provide foundational insights into the role of SUMOylation associated with the new biomarker SAE1 in RMS and its subtypes, paving the way for the development of personalized treatment strategies that leverage SUMO pathway inhibition.

This study established SAE1 as a novel independent prognostic biomarker in multiple cancers and identified its mechanistic role in HCC progression, suggesting its potential value for future translational research toward therapeutic development.

Our findings reveal a novel mechanism by which tumor cells evade p27-induced cellular growth arrest through p27 SUMOylation-mediated nuclear export. SAE1 may serve as a promising therapeutic target, and colchicine may be a potential treatment option for multiple types of cancer in clinical settings.

Functional analyses linked SAE1 to cell cycle and DNA replication pathways, suggesting a role in PAAD development. Our study indicates that SAE1 may promote PAAD through cell cycle pathways, with FOXA1 potentially regulating SAE1's abnormal behaviour.

Aberrant SUMOylation drives CCA progression by enhancing cell survival, proliferation, and shaping the tumor microenvironment. Targeting SUMOylation shows potential in inhibiting CCA growth, representing a promising therapeutic strategy.

The PPV of myositis antibodies for diagnoses of myositis or other myositis spectrum diseases vary considerably between individual autoantibodies. Higher PPVs can be expected with stronger band intensities and with the presence of ≥2 overlapping myositis antibodies.

Furthermore, the biological function of SAE1 may be associated with the PI3K/Akt/mTOR pathway. SAE1 will be a potential target for BC treatment.